A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013.

@article{Klotz2011API,
  title={A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013.},
  author={Laurence H. Klotz and Christopher James O'Callaghan and Keyue Ding and David Paul Dearnaley and Celestia S. Higano and Eric Mark Horwitz and Shawn Christopher Malone and S. Larry Goldenberg and Mary Krystyna Gospodarowicz and Juanita Crook},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 7_suppl},
  pages={3}
}
3 Background: In men with PSA recurrence after radical radiotherapy (RRT), intermittent androgen suppression (IAS) has been suggested by phase II trials to improve quality of life (QoL) but effects on survival are unknown. In this Intergroup randomized phase III trial, we compared IAS vs continuous androgen deprivation (CAD) to test for non-inferiority of IAS with respect to overall survival (OS). METHODS Eligible men had rising PSA > 3.0 ng/ml >1 year post RRT, either initial or salvage, for… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Advanced clinical states in prostate cancer.

The Urologic clinics of North America • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…